Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas (Registro nro. 22763)
[ vista simple ]
| 000 -Cabecera | |
|---|---|
| Campo de control interno | 03104nam a2200277 4500 |
| 001 - Número de control | |
| control field | ESSALUD |
| 005 - Fecha y hora de la última transacción | |
| Campo de control | 20260805001645.0 |
| 007 - Tipo material - Descripcion fisica - info general | |
| Tipo material - Descripcion fisica - info general | ta |
| 008 - Elementos de Longitud Fija - Información General | |
| Elementos de Longitud Fija - Información | t pe ||||| |||| 00| 0 spa d |
| 040 ## - Origen de la Catalogación | |
| Origen de la Catalogación | BMG |
| 041 ## - Idioma | |
| Idioma | eng |
| 100 ## - Autor | |
| Autor | Ruella, Marco |
| Rol del Autor | Autor |
| 9 (RLIN) | 53883 |
| 245 ## - Titulo | |
| Titulo | Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas |
| 300 ## - Páginas | |
| Paginación | páginas: 2440-2448 |
| 520 ## - Resumen | |
| Resumen | Background: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy is a standard treatment for relapsed or refractory B-cell non-Hodgkin lymphomas. Long-term results and curative potential remain uncertain.<br/>Methods: We evaluated long-term outcomes in 38 patients with relapsed or refractory B-cell non-Hodgkin lymphomas (24 patients with large B-cell lymphoma and 14 with follicular lymphoma) who had been treated with CTL019 (now called tisagenlecleucel) — autologous T cells expressing CD19-directed, 4-1BB–costimulated chimeric receptors. Lymphoma-free survival was defined as the time from the tisagenlecleucel infusion to relapse or lymphoma-related death. The incidence of non–relapse-related death and second primary cancer was estimated with the Aalen–Johansen method. The data-cutoff date was October 1, 2025.<br/>Results: At a median follow-up of 10.1 years (range, 7.9 to 11.5), no relapses had occurred beyond 5.4 years. The 10-year lymphoma-free survival was 32% (95% confidence interval [CI], 14 to 51) among patients with large B-cell lymphoma and 47% (95% CI, 20 to 71) among those with follicular lymphoma. In an analysis that included deaths from any cause, the 10-year progression-free survival was 17% (95% CI, 5 to 34) among patients with large B-cell lymphoma and 29% (95% CI, 9 to 52) among those with follicular lymphoma; the 10-year overall survival was 17% (95% CI, 5 to 34) and 50% (95% CI, 23 to 72), respectively. Persistent grade 2 or 3 neutropenia occurred in 2 patients (5%); no late anemia or thrombocytopenia was observed. A second primary cancer developed in 9 patients (10-year cumulative incidence, 21%). The 10-year non–relapse-related mortality was 18% (14% when deaths related to coronavirus disease 2019 were excluded). Higher CAR-transgene persistence appeared to be associated with long-term response. B-cell aplasia persisted in 44% of patients with a long-term response.<br/>Conclusions: Among patients with heavily pretreated B-cell non-Hodgkin lymphoma, a single infusion of tisagenlecleucel led to decade-long remissions (lymphoma-free survival) in approximately one third of the patients with large B-cell lymphomas and in nearly one half of those with follicular lymphoma. |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | LEUCEMIA |
| 9 (RLIN) | 33873 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | LINFOMA |
| 9 (RLIN) | 39360 |
| 650 ## - Temas - Descriptores | |
| Temas - Descriptores | TRATAMIENTOS EN ONCOLOGÍA |
| 9 (RLIN) | 53734 |
| 700 ## - Autor Personal | |
| Autor Personal | Paruzzo, Luca |
| 9 (RLIN) | 53884 |
| 700 ## - Autor Personal | |
| Autor Personal | Chong, Emeline R. |
| 9 (RLIN) | 53885 |
| 700 ## - Autor Personal | |
| Autor Personal | Chong, Elise A. |
| 9 (RLIN) | 53886 |
| 700 ## - Autor Personal | |
| Autor Personal | Landsburg, Daniel J. |
| 9 (RLIN) | 53887 |
| 700 ## - Autor Personal | |
| Autor Personal | Nasta, Sunita D. |
| 9 (RLIN) | 53888 |
| 773 0# - Revista (Relacion con el numero) | |
| Host Biblionumber | 22717 |
| Host Itemnumber | 22639 |
| Ciudad, Editorial | Massachusetts NEJM Group |
| Codigo barras item/ejemplar | NEJM006 |
| Titulo de la Revista | The New England Journal of Medicine |
| Número de control de registro | ESSALUD |
| ISSN | 0028-4793 |
| 942 ## - Elementos de Koha | |
| Tipo de Documento | Artículos |
| Fecha procesamiento | 2026-07-31 |
| Catalogador | SQB |
No hay ítems disponibles.